A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...

Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

For a drug that has been on the market for only a year, Eli Lilly and Co.’s anti-obesity treatment Zepbound has quickly made a huge name for itself, racking up more than $3 billion in sales and ...

With so many weight loss medications on the market, it's easy to feel overwhelmed by the options. From brand-name heavy ...

Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.

After a lucrative IPO in September, Richmond-based BioAge is seeing its biotech fortunes shift with its stock falling over 70 ...

BioAge Labs halts STRIDES Phase 2 trial of azelaprag after liver enzyme elevations, plans further analysis with updates ...

Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.

It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping a phase ...

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...

It's what most investors want more than anything else from their stocks. Three Motley Fool contributors think they've identified no-brainer growth stocks in the healthcare sector to buy in December.